SYMPK and cancer: We identified fusions in individual patients for which the 3’ oncogenes are significantly overexpressed relative to the cancer type supergroup (p < 0.1): PAX3–WWTR1 (2.1 and 3.0 zfpkm) and SYMPK–MEF2B (2.1 zfpkm) (Fig. 5).